Get an alert when a recall is issued.
Questions & Answers
Side Effects & Adverse Reactions
This product contains an antihistamine that may cause drowsiness and may have additive central nervous system (CNS) effects with alcohol or other CNS depressants (e.g., hypnotics, sedatives, tranquilizers). Antihistamines should be used with caution in patients with stenosing peptic ulcer, pyloroduodenal obstruction, and urinary bladder obstruction due to symptomatic prostatic hypertrophy and narrowing of the bladder neck. Administration of Carbetapentane may be accompanied by histamine release and should be used with caution in atopic children.
There is currently no legal information available for this drug.
FDA Safety Alerts
There are currently no FDA safety alerts available for this drug.
There is currently no manufacturer warning information available for this drug.
FDA Labeling Changes
There are currently no FDA labeling changes available for this drug.
V-COF Suspension is indicated for the symptomatic relief of coryza, nasal congestion, and cough associated with the common cold, sinusitis, allergic rhinitis, and other upper respiratory tract conditions. Appropriate therapy should be provided for the primary disease.
There is currently no drug history available for this drug.
V-COF Suspension is an antihistamine/nasal decongestant/antitussive combination for oral administration as a suspension.
Each 5 mL (one teaspoonful) of the Bubble Gum-flavored suspension for oral administration contains:
|Phenylephrine HCl||10 mg|
|Brompheniramine Maleate||6 mg|
|Carbetapentane Citrate||25 mg|
Inactive ingredients: Acesulfame, Artificial Bubble Gum, Aspartame, Citric Acid, FD&C Red #40, Glycerin, Methylparaben, Magnesium Aluminometasilicate, Purified Water, Sodium Benzoate, Sodium Citrate Dihydrate, Xanthan Gum and Galloquinate.
See Dosage and Administration section for further descriptive composition.